BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       


Cellexus Biosystems appoints JM Finn as Company’s Corporate Advisor17th August 2006 Cellexus Biosystems appoints JM Finn as Company’s Corporate Advisor

August 17th 2006 Cellexus Biosystems PLC (CBIO: Ofex) of Cambridgeshire, UK, has announced the appointment of JM Finn & Co. of London, UK, as the Company’s new Corporate Advisor, effective immediately.

Dr Kevin Auton, CEO of Cellexus Biosystems stated “We are delighted to be working with the team at JM Finn and are looking forward to an exciting 24 months ahead. Having only just listed on Ofex, we continue to implement our operational plan, which is on track and to budget. As we looked to the future, we saw that JM Finn would bring an added dimension to the Company as we prepare for a listing on London’s Alternative Investment Market (AiM) in 2007, when the timing is right for us. With JM Finn’s recently achieved status as an AiM Nominated Advisor, combined with their acknowledged expertise in Corporate Finance, we believe this appointment to be a fundamental step forward in achieving our long-term goals.”

The Directors of the issuer accept responsibility for this announcement

ENDS

About Cellexus Biosystems PLC

The Company is developing a range of new, value-added disposables to help researchers in the biopharmaceutical industry and academia develop new biopharmaceutical products from cell lines.

The Company has already developed its core technology from which a family of products is being created. Three products will be developed all based around the core technology - the CellexusBagTM – and will be marketed under the name: CellMaker LiteTM. These products potentially offer significant technological improvements over existing products for cell culture and cell growth in the developing disposables market.

Unlike competitive products, the CellexusBag products do not need to be stirred, shaken, rocked or rolled, which means the equipment used to manage the cell culture process is very simple and inexpensive. A patent application protecting the Company’s intellectual property was filed in December 2005.


Cellexus Biosystems PLC:

Dr Kevin Auton, CEO

New Tel: +44 1354 657 407

New Fax: +44 870 135 5536

New address: Cellexus Biosystems PLC

Hereward Innovation Centre, Hostmoor Avenue, March,

Cambridgeshire, PE15 0AX, United Kingdom

Email: kevin.auton@cellexusbiosystems.com

www.cellexusbiosystems.com 



CORPORATE ADVISER:

JM Finn & Co

Sailsbury House, London Wall, London EC2M 5TA

Mr Clive Carver

Tel: +44 207 628 9688

Email: clive.carver@jmfinn.com 

www.jmfinn.com 


MEDIA CONTACT FOR CELLEXUS BIOSYSTEMS PLC

Not This Limited

Tel: +44 1480 352 821

Email: info@notthislimited.co.uk

www.notthislimited.co.uk

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.